Table 6

Summary of STEP safety outcomes11–15

Trial (n)Doses and comparatorsDuration in weeksAE (%)GI AE (%)Discontinuation due to GI AE (%)Severe or BG-confirmed hypoglycemia
STEP 1 (n=1961)11SC semaglutide 2.4 mg Placebo6886.7 86.474.2 47.94.5 0.80.6 0.8
STEP 2 (n=1210)12SC semaglutide 2.4 mg SC semaglutide 1.0 mg Placebo6897.6 81.8 76.963.5 57.5 34.34.2 3.5 1.05.7 5.5 3.0
STEP 3 (n=611)13SC semaglutide 2.4 mg Placebo (+intensive behavioral therapy)6895.8 96.182.8 63.23.4 00.5 0
STEP 4 (n=902)14SC semaglutide (68 total weeks) SC semaglutide (20 weeks), then Placebo (48 weeks)6881.3 7549.1 26.12.4 2.20.6 1.1
STEP 5 (n=304)15SC semaglutide 2.4 mg PlaceboResults PendingResults PendingResults PendingResults Pending
  • Results for STEP 515 are pending at the time of writing this review.

  • AE, adverse events; BG, blood glucose; GI, gastrointestinal; SC, subcutaneous; STEP, Semaglutide Treatment Effect in People with Obesity.